Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod

International Journal of Dermatology

Volumn 42, Issue 7, 2003, Pages 576-579

  Seeberger, Josef ^a,b   Daoud, Saleh ^a,b   Pammer, Johannes ^a,b  

^a DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; IMIQUIMOD; PLACEBO;

ADOLESCENT; ADULT; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CRYOTHERAPY; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EROSION; FEMALE; HEADACHE; HUMAN; MALE; PROSPECTIVE STUDY; PRURITUS; SKIN BURNING SENSATION; SKIN LEISHMANIASIS; SKIN NODULE; SKIN ULCER; STANDARD; TOPICAL TREATMENT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AMINOQUINOLINES; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037931526     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2003.01955.x     Document Type: Conference Paper

References (16)

1. World Health Organization. Leishmaniasis. In: Thirteenth Programme Report. Special Programme for Research and Training in Tropical Diseases. Geneva: WHO Publications, 1997: 100-111.
2. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191-1199.
3. Hepburn NC. Cutaneous leishmaniasis. Clin Exp Dermatol 2000; 25: 363-370.
4. Desjeux P. Human leishmaniases: Epidemiology and public health aspects. World Health Stat Q 1992; 45: 267-275.
5. Röcken M. Erkrankungen durch Protozoen. In: Braun-Falco O, Plewig G, Wolff HH, eds. Dermatologie und Venerologie. Berlin, Heidelberg, New York: Springer-Verlag, 1996: 261-270.
6. Dahl MV. Imiquimod: An immune response modifier. J Am Acad Dermatol 2000; 43: S1-S5.
7. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-S11.
8. Ritter U, Korner H. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunol 2002; 24: 295-301.
9. Hennge UR, Benninghoff B, Ruzicka T, et al. Topical immunomodulators-progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001; 1: 189-198.
10. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action. J Infect Dis 1999; 179: 1485-1494.
11. Douba M, Mowakeh A, Wali A. Current status of cutaneous leishmaniasis in Aleppo, Syrian Arab Republic. Bull World Health Organ 1997; 75: 253-259.
12. Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol 2000; 43: S12-S17.
13. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326: 741-744.
14. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33: 1847-1851.
15. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007.
16. Gollnick H, Barasso R, Jappe U, et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12: 22-28.